FATE THERAPEUTICS INC. - COMMON STOCK

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

05 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

13 Dec 2022 07:00:02 By Nasdaq GlobeNewswire

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

10 Dec 2022 13:46:50 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

10 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

04 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

03 Nov 2022 15:01:02 By Nasdaq GlobeNewswire

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

03 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

24 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

05 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics to Participate at Upcoming September Investor Conferences

02 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

09 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

03 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

25 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer

30 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

28 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

03 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming May Investor Conferences

06 May 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress

04 May 2022 15:01:01 By Nasdaq GlobeNewswire